ASCO 2023 - Breast Cancer

Results of a large multicenter retrospective study confirmed that tucatinib in combination with trastuzumab and capecitabine was efficacious in patients with HER2-positive metastatic breast cancer with previous exposure to trastuzumab deruxtecan. Read More ›

Interim results from the Asia cohort of the HER2 REAL study found heterogeneous treatment patterns among patients with HER2-positive unresectable locally advanced or metastatic breast cancer progressing on HER2-directed therapies. Read More ›

Updated results of the phase 2 PERMEATE trial confirmed that pyrotinib plus capecitabine provided long-term survival benefit in patients with HER2-positive metastatic breast cancer and brain metastases. Read More ›

The phase 3 HER2CLIMB-05 trial is evaluating tucatinib plus trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive locally advanced or metastatic breast cancer. Read More ›

Updated results of the phase 3 randomized PRECIOUS trial demonstrated that dual HER2 blockade with pertuzumab re-treatment in combination with trastuzumab plus chemotherapy led to significant overall survival improvement compared with trastuzumab plus chemotherapy in patients previously treated with pertuzumab-containing regimens for HER2-positive locally advanced/metastatic breast cancer, but potential imbalances in chemotherapy during and after the study treatment period may have impacted the results. Read More ›

Page 2 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
CONQUER: the patient voice
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications